1	Associations Between Female Sex Hormones and Skeletal Muscle Ageing: The
2	Baltimore Longitudinal Study of Ageing
3	
4 5	Annabel J. Critchlow ^a , Sarah E. Alexander ^b , Danielle Hiam ^a , Luigi Ferrucci ^d , David Scott ^{a,c} , Séverine Lamon ^a
6	
7 8	^a School of Exercise and Nutrition Sciences, Institute for Physical Activity and Nutrition (IPAN), Deakin University, Geelong, Australia.
9 10	^b Cardiometabolic Health and Exercise Physiology, Baker Heart and Diabetes Institute, Melbourne, Australia
11	^c School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia.
12	^d National Institute on Aging, National Institutes of Health, Baltimore, Maryland, United States
13	
14	
15	Corresponding author:
16	A/Prof. Séverine Lamon
17	School of Exercise and Nutrition Sciences, Faculty of Health
18	Deakin University, 221 Burwood Hwy, Burwood 3125.
19	Australia
20	Ph (+61 3) 9244 5571
21	Email: severine.lamon@deakin.edu.au
22	
23	Author contact details:
24	Annabel Critchlow: annabel.critchlow@deakin.edu.au
25	Dr Sarah Alexander: sarah.alexander@baker.edu.au
26	Dr Danielle Hiam: danielle.hiam@deakin.edu.au
27	Dr Luigi Ferruci: <u>ferruccilu@grc.nia.nih.gov</u>
28	A/Prof David Scott: d.scott@deakin.edu.au
29	
30	Word count: 4461
31	Number of figures: 1
32	Number of tables: 2
33	Number of references: 38

1

34 Abstract

Background: To date, most research investigating the influence of circulating sex hormones on ageing female skeletal muscle has been cross-sectional and focused only on dichotomised young and old, or pre- versus post-menopausal groups. This excludes an important transitional period from high to low circulating oestrogen. Using secondary data from the Baltimore Longitudinal Study of Aging, this study aimed to investigate cross-sectional and longitudinal associations between circulating sex hormones and skeletal muscle mass and function across a continuum of ages.

41 **Methods**: Multiple and binomial linear regression was used to map cross-sectional (n=319) and 42 longitudinal (n=83) associations between circulating sex hormones (oestradiol (E2), free oestradiol 43 index (FEI), free (TT) and bioavailable testosterone (BioT), testosterone/oestradiol ratio (T/E2)) and 44 skeletal muscle mass and function in healthy females. Cross-sectional models analysed females across 45 an ageing continuum (24-89 years) and longitudinal associations were tested across 4-6 years of 46 ageing in females over 50 years old. Models were adjusted for age, height, physical activity, 47 comorbidities, and ethnicity.

48 **Results**: Cross-sectionally, serum E2 and FEI were positively associated with relative appendicular 49 lean mass (ALM; β =0.28 and 0.20, respectively, p<0.05) and thigh muscle percentage (β =0.19 and 50 0.15, respectively, p < 0.05). E2 and FEI were negatively associated with total body fat percentage (β =-51 0.30 and -0.21, respectively, p < 0.05). BioT was positively associated with absolute ALM ($\beta = 0.13$, 52 p < 0.05) and total body fat percentage ($\beta = 0.18$, p < 0.05). TT was negatively associated with total body 53 fat percentage (β =-0.14, p<0.05). The T/E2 ratio was negatively associated with thigh muscle CSA 54 (β =-0.08, p<0.05) and hamstring strength (β =-0.12, p<0.05). Across 4-6 years, Δ E2 and Δ FEI were 55 positively associated with the change in ALM (β =0.29 and 0.42, respectively, p<0.05), and Δ FEI was 56 positively associated with the change in handgrip strength (β =0.17, p<0.05). Δ TT and Δ BioT were 57 negatively associated with the change in relative ALM (β =-0.25 for both, p<0.05) and relative 58 quadriceps strength (β =-0.12 and -0.27, respectively, *p*<0.05)

59 **Conclusion**: This study demonstrates novel associations between sex hormone levels and skeletal 60 muscle in females across a wide continuum of ages. We also demonstrate that longitudinal 61 fluctuations in circulating sex hormones must be considered to gain a comprehensive understanding of 62 female muscle ageing.

63

64 Keywords: oestrogen, ovarian hormones, skeletal muscle, ageing

65 Introduction

The World Health Organization [1] predicts the global population above 60 years of age will double from 2019 to 2050. However, improvements to increase the lifespan have not been matched by advancements in the health span; that is, the length of time a person remains healthy, not just alive. While females live longer than males [2], those additional years are spent in significantly poorer health, highlighting a large disparity between the health span and lifespan in females compared to males [3].

72 Ageing is associated with a progressive loss of muscle mass and function which presents an 73 increasingly substantial public health concern. Age-related muscle wasting is significantly associated 74 with many adverse outcomes, including reduced independence and quality of life, and increased 75 chronic disease, hospitalisation, and mortality [4]. While the prevalence of age-related muscle loss is 76 seemingly similar between the sexes [5], evidence suggests that the patterns, and therefore the 77 underlying molecular mechanisms of muscle ageing may be sex-specific. For example, females 78 undergo a rapid decline in knee extensor strength ~20 years earlier than males [6]. In addition, while 79 both sexes share the same direction of changes to the transcriptome with ageing, the magnitudes of 80 change to differentially expressed genes differs between the sexes from young and old individuals [7].

81 Testosterone and oestrogen are the predominant sex hormones in males and females, respectively. 82 While they are produced by both sexes, their profiles vary drastically across the lifespan. Females 83 undergo a dramatic decline in endogenous oestrogen production starting ~ 40 years of age [8], meaning they can spend over a 3rd of their life in an oestrogen-deficient state. A steep reduction in 84 85 total and bioavailable (i.e. not bound to sex hormone-binding globulin (SHBG)) testosterone occurs in 86 the early reproductive years, which stabilises around menopause [9]. In contrast, male testosterone 87 production remains largely consistent across adult life with a gradual decline in later decades [9]. 88 Oestrogen and testosterone elicit effects in multiple tissues, including skeletal muscle, by binding to 89 the oestrogen (ER) and androgen receptor (AR), respectively [10]. In females, bioavailable 90 testosterone is associated the maintenance of muscle mass [11], and oestrogen may regulate the 91 maintenance of muscle mass, strength, and mitochondrial function [12].

92 A recent systematic review by our group found a consistent reduction in muscle mass and handgrip 93 strength across the menopausal transition, however many studies show no association between 94 oestradiol concentrations (E2, the major endogenous form of oestrogen) and muscle mass or function 95 in pre- or postmenopausal females [13]. The cross-sectional nature and dichotomisation of age groups 96 in this body of evidence is a limitation because it prevents conclusions to be drawn about the effects 97 of changes in sex hormone concentrations on muscle health over time. Only one study has explored 98 this association in a longitudinal manner, reporting no relationship between baseline circulating E2 or 99 testosterone and the loss of appendicular lean mass or knee extensor strength over 3 years in

postmenopausal females [14]. However, it remains largely unknown how age-related fluctuations in sex hormones impact the regulation of skeletal muscle across a broader age range, as associations between the changes in sex hormones and skeletal muscle health across ageing and the menopausal transition are still to be mapped.

This study used data from the Baltimore Longitudinal Study of Aging (BLSA, [15]) to address two research questions. First, we aimed to determine the cross-sectional associations between circulating female sex hormone concentrations and skeletal muscle mass and function across a continuum of ages and hormonal status (24 to 89 years). Secondly, we aimed to investigate the longitudinal associations between circulating sex hormone concentrations and the changes in muscle mass and function that occurred over a 4–6-year period in females aged 50 to 87 years.

110 Methods

111 Study Population

This is a secondary analysis of data from the BLSA [15], an ongoing prospective study that aims to extensively map the process of healthy ageing [15]. Testing is carried out at the National Institute of Ageing Clinical Research Unit in Baltimore, Maryland. Healthy participants between 20-96 years without any chronic disease or cognitive impairment were recruited. Data collected between 2003 and 2023 were utilised in this analysis. Participants under 60 years old were tested every 4 years, 60–79year-olds were tested every 2 years, and those above 80 years were tested every year.

118 Inclusion Criteria

119 Inclusion criteria for the present study included female BLSA participants with no missing variables 120 of interest (serum sex hormones, DXA body composition, handgrip, hamstring, and quadriceps 121 strength, and confounding variables). Data from females at their first visit was used for the cross-122 sectional analysis if there were no missing variables (n=319). From these participants, females >50 123 years were included in the longitudinal analysis (n=83) if they had a follow up visit 4-6 years later 124 with all the required sex hormone and outcome variables. If they had multiple visits within this time 125 frame, data from the latest was used. As the BLSA recruit only healthy individuals at baseline, there 126 were no additional exclusion criteria specific to this study.

127 Measures

128 Serum Hormone Analysis

Fasted (12 h) blood samples were taken from participants in the morning of each visit and immediately centrifuged at 4°C. Serum was aliquoted and stored at -80°C. Fasted serum hormone concentrations of E2 (ng/dL) and total testosterone (TT, ng/dL) were determined by high-performance liquid chromatography-tandem mass spectrometry (LC/MS; Esoterix part of LabCorp, Calabasas

133 Hills, CA). SHBG concentrations (nmol/L) were analysed via immunoradiometric assay (Esoterix part

- 134 of LabCorp). To determine bioavailable testosterone (BioT, ng/dL), ammonium sulphate was used to
- 135 separate SHBG-bound hormones from albumin-bound and free hormones (Esoterix part of LabCorp).
- 136 E2, TT, and BioT concentrations were converted to SI units (pmol/L, nmol/L and nmol/L,
- 137 respectively). The free oestrogen index (FEI) was calculated by dividing E2 (pmol/L) by SHBG
- 138 (nmol/L) and multiplying by 100. The testosterone to oestrogen (T/E2) ratio was calculated by
- 139 dividing TT (nmol/L) by E2 (pmol/L).
- 140 Body Composition
- 141 Body composition measures including appendicular lean mass (ALM, kg), leg lean mass (LLM, kg),

142 and total body fat mass (TBFM, kg) were assessed via whole-body DXA (Prodigy Scanner, GE,

143 Madison, WI) scans with software version 10.51.006. The scanner was calibrated daily. Reliability has

- been assessed in 12 older (>65 years) males, showing <1% difference in fat mass (kg) between 2
- scans, 6 weeks apart [16]. Relative ALM (kg.kg⁻¹) was calculated by dividing appendicular lean mass
- 146 (kg) by total body fat mass (kg). Thigh muscle cross-sectional area (CSA, cm²), subcutaneous fat area

147 (cm^2) , intramuscular fat area (cm^2) , and muscle density (HU) were assessed using computerised

148 tomography (CT) cross-sectional images of the mid-thigh (Somatom Sensation 10, Siemens, Malvern,

- 149 PA). Thigh muscle percentage was calculated by dividing total thigh CSA (cm²) by muscle CSA
- 150 (cm²). CT images were analysed and quantified with Geanie 2.1 software (BonAlyse Oy, Jyvaskla,
- 151 Finland).

152 Muscle Function

153 Handgrip strength (kg) was assessed using a Jamar Hydraulic hand dynamometer (Patterson Medical, 154 Warrenville, IL). Participants sat with their arm extended to 180° or shoulder height and were 155 instructed to squeeze the dynamometer as hard as possible. Maximum force was measured in three 156 trials on each hand, and the best of 6 were used in the analysis. The average of the left and right hand 157 was used in the analysis. Lower limb strength was measured using the Kin-Com isokinetic 158 dynamometer (Kin-Com model 125E version 3.2, Chattanooga Group, Chattanooga, TN) from 2003 159 to 2011, and the Biodex Multi-Joint System-Pro dynamometer (Biodex Medical System, Advantage 160 Software V4.X, Inc., Shirley, NY) from 2011 to 2023. Quadriceps strength (isokinetic knee 161 extension; Nm) and hamstring strength (isokinetic knee flexion; Nm) was measured at an angular 162 velocity of 30°/s and 180°/s. Participants were asked to extend/flex their knee as hard as possible 163 through a range of motion set between 100-160°. They completed two practice trials, followed by 164 three test trials. The highest peak torque value was included in the analysis. Peak torque normalised to leg lean mass (Nm/kg) and thigh muscle CSA (Nm/cm²), were calculated by dividing hamstring and 165 166 quadriceps peak torque (Nm) by leg lean mass (kg) and thigh muscle CSA (cm²), respectively.

167 Physical Function

168 Gait speed was assessed by instructing participants to walk 400 m as fast as possible after a warm-up 169 of 2.5 minutes at a usual gait speed. Chair stand ability was measured by asking participants to fold 170 their arms and stand up from a chair 10 times. The pace of the first 5 chair stands (stands/s) was 171 recorded. Participants completed three tests (6 m walk test, chair stand test, and standing balance) to 172 comprise the Short Physical Performance Battery (SPPB), a validated assessment of mobility. 173 Performance in each of the 3 tests was scored from 0 (worst) to 4 (best) and summed to give a total 174 out of 12, as previously described [17]. Finally, participants were categorised as a faller if they had at 175 least one self-reported fall in the previous 12 months.

176 Potential confounding variables

Demographic information was collected from participants via an interview, including age, ethnicity, comorbidities, and total physical activity in the previous two weeks. The age adjusted Charlson comorbidity index (ACCI) was determined as previously described [18]. Briefly, a score is assigned to each comorbid condition, with additional points for increasing age groups.

181 Statistical Analysis

Statistical analysis was completed using Stata software version 17.0 (StataCorp, College Station, TX). Data are presented as mean \pm SD and statistical significance was accepted as p < 0.05. Participants with values that were deemed physiologically implausible (>10 SDs) were excluded. One participant was excluded from the cross-sectional analysis because handgrip strength was >300kg. Forty and 21 participants were excluded from the cross-sectional and longitudinal analysis, respectively, because their hormone levels were below zero. Paired t-tests were performed to determine the differences between variables at baseline and follow-up.

189 Multiple regression

190 Multiple linear regression was performed to determine the cross-sectional relationships between 191 circulating sex hormones, body composition (from DXA), and muscle function. Further outcome 192 variables were assessed in subsets of participants where measured, including thigh CT measures and 193 physical function. Additional models were performed to determine cross-sectional associations 194 between self-reported menopausal and hormonal supplementation status and all muscle outcomes. In 195 the longitudinal analysis, multiple regression models were performed to determine the relationship 196 between the change in sex hormone levels and the change in outcome measures across 4-6 years in 197 females over 50 years. Further analysis was completed to measure the longitudinal associations 198 between baseline menopausal status and HRT use and the change in muscle outcome measures.

Each model was adjusted for age, ethnicity, height, ACCI, and physical activity. Where significant andopposing associations were detected for serum oestradiol (E2 or FEI) and testosterone (TT or BioT),

both hormones were added to the model to determine if they remained significantly and independently associated with the outcome variable.

203 Multicollinearity was assessed by variation inflation factors with a threshold of 5. No variables 204 displayed collinearity. Normality of residuals was confirmed by plotting a histogram of studentised 205 residuals. Homoscedasticity was assessed by plotting fitted versus predicted residuals. Some 206 heteroscedasticity was observed, so robust standard errors were used. To determine the magnitude of 207 the relationships, the z-score was calculated for all independent (E2, FEI, TT, BioT, SHBG, and T/E2 208 ratio) and outcome measures (body composition, muscle function, and physical function), where zero 209 equals the mean, and 1 equals the standard deviation. Where the standardised coefficient was <0.2, the 210 effect size of the relationship was considered 'small', 0.2 to 0.5 denotes a 'medium' effect size, and 211 >0.5 represents a 'large' effect size.

212 Binomial linear regression

213 In females over 50 years of age, binomial linear regression models were used to determine the cross-

214 sectional relationship between sex hormone levels and dichotomous physical function outcome

215 measures (mobility disability and fallers).

216 **Results**

217 Participant characteristics

218 Characteristics of the participants included in the cross-sectional and longitudinal analysis are shown 219 in Supplementary Tables S1 and S2, respectively. Self-reported menopausal status and hormonal 220 supplementation is shown in Table S3. In the longitudinal analysis, there was a 50.8% reduction 221 (p < 0.05) from baseline (mean age: 64.41 ± 10.99 years) to follow up (4.86 ± 0.88 years later) in 222 circulating E2, but not in other hormones. In body composition measures, there was a 4.6% reduction 223 in thigh muscle CSA (p < 0.05), and a 3.9% reduction in thigh muscle density (p < 0.05). Regarding 224 muscle function, there was a reduction in absolute and relative hamstring strength at 180 °/s 225 (absolute: -12%, relative to LLM: -11.2%, relative to muscle CSA: -8.4%, p < 0.05), and absolute and 226 relative quadriceps strength at 180°/s (absolute: -8.0%, relative to LLM: -7.5%, p < 0.05) and 30°/s 227 (absolute: -8.2%, relative to LLM: -8.1%, relative to CSA: -4.5%, p < 0.05). There was a 9% increase 228 in 400 m walk time (p < 0.05).

229 Cross-sectional analysis

Adjusted cross-sectional associations between circulating sex hormones and skeletal muscle outcome measures in females between 24-89 years are displayed in Table 1. Amongst the body composition measures, circulating E2 and FEI were positively associated with relative ALM (kg, p < 0.05). BioT was positively associated with absolute ALM (kg, p < 0.05) but negatively associated with relative

234 ALM (kg, p < 0.05). E2, FEI, and TT were negatively associated with total body fat percentage 235 (p < 0.05), but there was a positive association for BioT (p < 0.05). E2 and FEI were positively 236 associated with thigh muscle percentage (p < 0.05), and T/E2 ratio was negatively associated with thigh muscle CSA (cm², p < 0.05). BioT was positively associated with subcutaneous and 237 238 intramuscular fat (kg, p < 0.05), while E2 was negatively associated with subcutaneous fat (kg, 239 p < 0.05). In muscle function models, T/E2 ratio was negatively associated with hamstring peak torque 240 (Nm) at 180°/s (p < 0.05) and BioT was positively associated with 400 m walk time (s, p < 0.05; Table 241 1). The binomial linear regression results are displayed in Table S4. There were no significant 242 associations between any hormones and indices of mobility disability or falls in females over 50 years 243 (n=238).

244 Cross-sectional associations between menopausal status, hormonal supplementation and muscle 245 outcomes are displayed in Table S5. Postmenopausal status was positively associated with total body 246 fat (%, p < 0.05), subcutaneous fat (kg, p < 0.05), and intramuscular fat (kg, p < 0.05), and negatively associated with relative ALM (kg, p < 0.05) and thigh muscle CSA (cm², p < 0.05). Amongst 247 248 postmenopausal females, use of HRT was positively associated with handgrip strength (kg, p < 0.05). 249 In premenopausal females, use of the HCP was positively associated with relative quadriceps strength 250 normalised to leg lean mass at 30° /s (Nm/kg, p < 0.05). It was also negatively associated with muscle 251 density (HU, p < 0.05), absolute and relative hamstring strength (Nm and Nm/kg, p < 0.05), and relative

quadriceps strength normalised to thigh muscle CSA at $30^{\circ}/s$ (Nm/cm², p < 0.05).

Where E2/FEI and BioT were found to have opposite associations with a muscle outcome, both hormones were included in the model. BioT was added to the cross-sectional models investigating the relationship between E2 and relative ALM, total body fat percentage, and subcutaneous fat, and the relationship between FEI and relative ALM and total body fat. In all models, oestradiol (E2 or FEI) remained significantly associated positively with relative ALM and negatively with body fat percentage and subcutaneous fat, while BioT remained significantly associated in the opposite direction (p < 0.05; Table S6).

260 Longitudinal analysis

261 Adjusted longitudinal associations between the change in circulating sex hormones and the change in 262 skeletal muscle outcome measures in females over 50 years are displayed in Table 2. Regarding body 263 composition, $\Delta E2$ and ΔFEI were positively associated with the change in ALM (kg, p < 0.05). ΔTT 264 and \triangle BioT were negatively associated with the change in relative ALM (kg, p < 0.05). \triangle FEI was 265 negatively associated with the change in thigh muscle percentage (p < 0.05), and positively associated 266 with the change in subcutaneous and intramuscular fat (kg, p < 0.05). Regarding muscle function, ΔFEI 267 was positively associated with the change in handgrip strength (kg, p < 0.05), but negatively associated 268 with the change in quadriceps strength (Nm) at 180°/s (p < 0.05). Similarly, ΔTT and $\Delta BioT$ were

269 negatively associated with the change in relative quadriceps strength at 30°/s when normalised to leg

270 lean mass (Nm/kg, p < 0.05). Finally, Δ BioT was positively associated with the change in 400 m walk

271 time (s, *p*<0.05).

272 Longitudinal associations between baseline menopausal status, HRT use and the change in muscle 273 outcomes across 4-6 years in females over 50 years old are displayed in Table S7. Postmenopausal 274 status at baseline was positively associated with the change in ALM (kg, p < 0.05) and thigh muscle 275 CSA (cm², p < 0.05). Being a current HRT user at baseline was negatively associated with the change 276 in handgrip strength (kg, p < 0.05), while previous use of HRT was positively associated with the 277 change in intramuscular fat (kg, p < 0.05) and relative hamstring strength normalised to muscle thigh CSA (Nm/cm², p < 0.05), and negatively associated with the change in thigh muscle CSA (cm², 278 279 *p*<0.05).

280 Discussion

A summary of results is displayed in Figure 1. To the best of the authors knowledge, this is the first study to 1) map cross-sectional associations between sex hormones and muscle outcomes in a wide continuum of ages across the adult lifespan, and 2) investigate how changes to circulating sex hormones beyond 50 years of age associate with changes to muscle mass and function over 4-6 years.

285

Orate and Maniaki	E	2	F	EI	Т	т	Bi	оТ	T/E	2	
Outcome variable	es	CS	L	CS	L	CS	L	CS	L	CS	L
Muscle mass ALM Relative ALM	ALM		Ð		Ð			Ð			
	Relative ALM	lative ALM \bigoplus									
	Thigh muscle CSA									•	
	Thigh muscle %	Ð		0	•						
Fat mass	Total body fat %	0		0		•		Đ			
	Subcutaneous fat	0			Ð			Ð			
	Intramuscular fat				Ð			Ð			
Muscle function	Handgrip strength				•						
	Hamstring strength									•	
	Quadriceps strength				0						
	Relative quadriceps strength						•		•		
	400m walk time							•	Ð		

Figure 1. Summary of cross-sectional and longitudinal associations between serum sex hormones and body composition and muscle function. The size of the symbol corresponds to the effect size of the association: small icons denote $\beta < 0.2$, medium icons denote β between 0.2 - 0.5. Green icons show positive associations, and red icons show negative associations. ALM: appendicular lean mass; BioT: bioavailable testosterone; CS: cross-sectional; E2: oestradiol; FEI: free oestrogen index; L: longitudinal; TT: total testosterone; T/E2: ratio of total testosterone to E2.

286

287 Sex hormones and body composition:

288 Oestradiol

289 This study highlighted a positive cross-sectional association between serum E2 levels (total and FEI) 290 and measures of muscle mass (relative ALM and thigh muscle percentage) in females across the 291 lifespan, independent of age. Additionally, both total serum E2 and FEI were negatively associated 292 with total body fat percentage and thigh subcutaneous fat, suggesting a potential role for E2 in 293 maintaining the proportion of muscle mass throughout ageing. This is line with previous mechanistic 294 work in animals highlighting an anabolic role of E2 in skeletal muscle [12]. Interestingly, this 295 contradicts with many previous cross-sectional studies investigating samples of postmenopausal 296 females, which demonstrate no associations between serum oestradiol or FEI and muscle mass [13]. 297 This is likely due to the inclusion of postmenopausal females that, by definition, have very low serum 298 E2 concentrations, so there is unlikely to be large variation between participants. In contrast, the 299 current cohort spans a wide continuum of adulthood (24 to 89 years) and E2 concentrations (5 to 1872 300 pmol/L), thereby allowing us to understand how large age-related fluctuations in oestrogens impact 301 the regulation of muscle mass over the lifespan.

302 In the longitudinal analysis of females over 50 years old, the change in serum E2 and FEI across the 303 5-year follow up was positively associated with the change in absolute ALM, suggesting females with 304 a larger decline in serum E2 and FEI have a greater decline in muscle mass. This further emphasises a 305 potential role for total and free E2 in anabolic regulation, in line with the cross-sectional findings. The 306 only longitudinal study to have previously investigated this found no association between serum E2 307 and the loss of ALM over 3 years in 49 postmenopausal females [14]. However, baseline hormone 308 concentrations were used in the model, as opposed to the change in hormone concentration from 309 baseline to follow up. This suggests that it may not be baseline E2 concentration, but the magnitude of 310 change in E2 concentration from baseline, that determines the extent of muscle loss post-menopause. 311 It is therefore important to understand the temporal nature of the relationship between E2 and skeletal 312 muscle, where the population is displaying rapid changes in both hormone concentrations and muscle 313 mass and function.

Surprisingly, the change in serum FEI was negatively associated with the change in thigh muscle percentage, and positively associated with the change in thigh subcutaneous and intramuscular fat. Together this suggests that a decline in serum FEI coincides with an increased relative proportion of muscle in the thigh, potentially due to declines in both subcutaneous and intramuscular fat content, rather than an inverse relationship between FEI and muscle mass. We suggest this is the case, as the change in FEI was positively associated with absolute ALM. Although, DXA measures of ALM do

320 not appropriately distinguish muscle from intramuscular fat, which may have exaggerated this 321 positive association, highlighting the importance of including direct measures of muscle and fat 322 infiltration from CT scans.

323 Testosterone

In the cross-sectional analysis, serum TT concentrations were negatively associated with total body fat percentage and no other compositional measures. This in line with previous studies showing a lack of association between serum TT and lean mass or muscle CSA in both pre- [11] and postmenopausal [19-22] females, although this is the first study to investigate the association across the entire adult lifespan. Instead, bioavailable (non-SHBG bound) or free (non-protein bound) forms of testosterone appear to be more relevant in this context, as many studies have reported a positive association with lean mass [11, 19, 20, 22-25] or muscle CSA [26-28].

331 In line with these studies, BioT concentration was positively associated with absolute ALM. However, 332 it was also positively associated with measures of fat mass (total body fat percentage, and thigh 333 subcutaneous and intramuscular fat), explaining the negative association between BioT and relative 334 ALM; an increase in fat tissue corresponds to a reduction in relative ALM, as relative ALM is indexed 335 to total body fat mass. While change in muscle and fat mass across 4-6 years of ageing may occur in 336 the same direction (i.e. both gained or lost), the resulting relative proportion of each tissue differs. A 337 similar trend was noted in the longitudinal analysis, as both the change in TT and BioT from baseline 338 to follow up were negatively associated with the change in relative ALM.

339 Sex hormones and muscle function:

340 Oestradiol

341 No significant cross-sectional associations were present between serum E2 or FEI and any measure of 342 muscle function. This contrasts with Pöllanen et al. [29] who found a positive association between 343 serum E2 and relative quadriceps femoris strength in an albeit much smaller sample (n=25) of pre-344 and postmenopausal females. Importantly, age was not included as a confounding variable, therefore 345 these findings may just reflect the loss of both serum E2 and muscle strength with age. Indeed, when 346 age was included as a covariate, Bochud et al. [30] found no cross-sectional association between 347 urinary E2 concentrations and handgrip strength in a sample of 366 females between 18 and 90 years 348 of age.

The change in serum FEI was significantly and positively associated with the change in handgrip strength across 4-6 years, suggesting that a greater decline in free oestradiol is related to a greater decline in handgrip strength, a common proxy for overall muscle and physical function [31]. In contrast, the change in serum FEI was negatively associated with the change in absolute quadriceps

strength. This finding is unexpected but may indicate the presence of other confounding factors that are not yet identified. Rolland et al. [14] found no association between serum E2 and the loss of muscle strength over 3 years in postmenopausal females, but higher serum oestrone (E1) was similarly associated with a greater loss of muscle strength. E1 is an endogenous form of oestrogen which becomes predominant after the menopause-related decline of serum E2 [29]. While less potent than E2, its role within the muscle remains largely understudied, highlighting a target for future research, particularly in postmenopausal females.

360 Testosterone

361 Similarly to E2, both serum TT and BioT were not cross-sectionally associated with any measures of 362 muscle strength. This is in line with other studies that investigated younger [11, 26], older [32] or both 363 pre- and postmenopausal [29] females. To our knowledge, this is the first study to investigate 364 longitudinal associations between serum testosterone and muscle function in ageing females. The 365 change in both TT and BioT levels were negatively associated with the change in relative quadriceps 366 strength, suggesting that an increase in serum testosterone concentration coincides with a decrease in 367 lower limb strength. While this is unexpected, it is further supported by the positive cross-sectional 368 and longitudinal associations between BioT and gait speed. This suggests that greater concentrations 369 of, or changes to, circulating bioavailable testosterone associate with worse physical function in the 370 lower limbs of ageing females. This is surprising as testosterone supplementation in postmenopausal 371 females can elicit anabolic effects in skeletal muscle [33], although basal molecular regulation of 372 muscle by testosterone has not yet been investigated in females.

373 The T/E2 ratio and skeletal muscle ageing:

374 When investigating their effects within skeletal muscle, circulating sex hormones have most often 375 been considered individually, but their production is closely linked due to common biosynthetic 376 pathways. For example, testosterone is converted to oestradiol via the enzyme aromatase; a process 377 that can be quantitatively assessed by the T/E2 ratio, where a greater T/E2 ratio indicates less 378 synthesis of E2 from testosterone, and therefore lower aromatase activity [34]. In premenopausal 379 females, the ovaries are responsible for ~95% of circulating oestradiol production, but the peripheral 380 conversion of testosterone to E2 becomes more physiologically relevant after menopause when the 381 ovaries cease E2 production [34, 35]. We observed a negative cross-sectional association between the 382 T/E2 ratio and muscle mass (thigh muscle CSA) and strength (hamstring peak torque), suggesting that 383 a lower conversion rate of testosterone to E2 is concomitant to poorer muscle quality across ageing. 384 Further research should be conducted to understand the contribution of varying oestrogen synthesis 385 pathways in the regulation of skeletal muscle throughout ageing in females.

386 Limitations

387 While this study provides novel insights into the relationship between circulating sex hormones and 388 skeletal muscle ageing, it is not without limitations. Menstrual cycle phase has not been controlled 389 when scheduling premenopausal participant visits. Common measures of acute skeletal muscle 390 function are unlikely to be altered according to menstrual cycle phase [36], however, circulating E2 391 levels can vary from 70-1500 pmol/L between the early follicular and ovulatory phase [37]. 392 Therefore, depending on the phase in which the blood sample was collected, the relationship between 393 circulating E2 and skeletal muscle outcomes may significantly differ. Future studies should test all 394 premenopausal participants within the early follicular phase as previously described [38], where 395 serum E2 is at its lowest or 'basal' level.

Secondly, premenopausal participants provided information on HCP use, but many other forms of hormonal contraception are commonly used and provide external doses of oestrogen or progesterone, including the intrauterine devices, implant, injections and skin patches. Therefore, a more comprehensive understanding of exogenous sex hormone profiles is required to improve reliability of the findings.

Finally, approximately one third of participants in this study were non-white, suggesting that these findings are representative of a range of ethnicities. However, due to the inclusion criteria of the BLSA, participants are likely healthier than the general population. Therefore, the generalisability of these findings to females with multiple chronic health conditions is questionable.

405 Conclusion

This study has demonstrated novel and divergent cross-sectional and longitudinal associations between circulating sex hormones and skeletal muscle outcomes in females across the ageing continuum. This emphasises the need to consider the temporal aspect of sex hormone regulation in ageing female muscle, particularly across the transitional period from a high to low state of circulating oestrogen. Future research should aim to identify molecular mechanisms of oestrogen action in human female skeletal muscle, to determine how ageing-induced oestrogen deficiency contributes to a loss of muscle mass and function in the later decades of life.

413 Additional Information

414 Funding

SL is funded by an Australian Research Council Future Fellowship (FT210100278). DS is funded by a
National Health and Medical Research Council (NHMRC) Australia Investigator Grant
(GNT1174886).

418 Ethical Standards

419	Written informed consent was provided by all participants at every visit and the BSLA protocol was
420	approved by the National Institute of Health (NCT00233272). This study (project number: 2023-029)
421	has been declared exempt from ethical review on 07/02/2023 by the Deakin University Human
422	Research Ethics Committee (DUHREC) as it comprises only of secondary data analysis. Supported in
423	part by the Intramural Research Program of the National Institute on Aging, NIH. Baltimore, MD,
424	USA
425	Conflicts of Interest
426	The authors declare no conflicts of interest.
427	
428	
429	
430	
431	
432	
433	
434	
435	
436	
437	
438	
439	
440	
441	
442	

443 References

444 1. World Health Organization. Ageing and health. 2024. <u>https://www.who.int/news-room/fact-</u>
445 sheets/detail/ageing-and-health. Accessed 22/07/2024.

446 2. Australian Bureau of Statistics. Twenty years of population change. 2020.
447 <u>https://www.abs.gov.au/articles/twenty-years-population-change</u>. Accessed 22/07/2024.

448 3. Austad SN, Fischer KE. Sex differences in lifespan. Cell metabolism. 2016;23:1022-33.

449 4. Peterson SJ, Braunschweig CA. Prevalence of Sarcopenia and Associated Outcomes in the
450 Clinical Setting. Nutrition in Clinical Practice. 2016;31:40-8. doi:doi.org/10.1177/0884533615622537

5. Petermann-Rocha F, Balntzi V, Gray SR, Lara J, Ho FK, Pell JP, et al. Global prevalence of
sarcopenia and severe sarcopenia: a systematic review and meta-analysis. Journal of Cachexia,
Sarcopenia and Muscle. 2022;13:86-99. doi:doi.org/10.1002/jcsm.12783

454 6. Haynes EMK, Neubauer NA, Cornett KMD, O'Connor BP, Jones GR, Jakobi JM. Age and
455 sex-related decline of muscle strength across the adult lifespan: a scoping review of aggregated data.
456 Appl Physiol Nutr Metab. 2020;45:1185-96. doi:10.1139/apnm-2020-0081

457 7. de Jong J, Attema BJ, van der Hoek MD, Verschuren L, Caspers MPM, Kleemann R, et al.
458 Sex differences in skeletal muscle-aging trajectory: same processes, but with a different ranking.
459 Geroscience. 2023;45:2367-86. doi:10.1007/s11357-023-00750-4

Frederiksen H, Johannsen TH, Andersen SE, Albrethsen J, Landersoe SK, Petersen JH, et al.
 Sex-specific Estrogen Levels and Reference Intervals from Infancy to Late Adulthood Determined by
 LC-MS/MS. J Clin Endocrinol Metab. 2020;105:754-68. doi:10.1210/clinem/dgz196

463 9. Handelsman DJ, Sikaris K, Ly LP. Estimating age-specific trends in circulating testosterone
464 and sex hormone-binding globulin in males and females across the lifespan. Annals of Clinical
465 Biochemistry. 2016;53:377-84. doi:10.1177/0004563215610589

466 10. Alexander SE, Pollock AC, Lamon S. The effect of sex hormones on skeletal muscle
467 adaptation in females. European Journal of Sport Science. 2022;22:1035-45.
468 doi:10.1080/17461391.2021.1921854

Alexander SE, Abbott G, Aisbett B, Wadley GD, Hnatiuk JA, Lamon S. Total testosterone is
not associated with lean mass or handgrip strength in pre-menopausal females. Scientific Reports.
2021;11:10226. doi:10.1038/s41598-021-89232-1

472 12. Pellegrino A, Tiidus PM, Vandenboom R. Mechanisms of Estrogen Influence on Skeletal
473 Muscle: Mass, Regeneration, and Mitochondrial Function. Sports Med. 2022;52:2853-69.
474 doi:10.1007/s40279-022-01733-9

475 13. Critchlow AJ, Hiam D, Williams R, Scott D, Lamon S. The role of estrogen in female skeletal
476 muscle aging: A systematic review. Maturitas. 2023;178:107844.
477 doi:doi.org/10.1016/j.maturitas.2023.107844

Rolland YM, Perry HM, 3rd, Patrick P, Banks WA, Morley JE. Loss of appendicular muscle
mass and loss of muscle strength in young postmenopausal women. J Gerontol A Biol Sci Med Sci.
2007;62:330-5. doi:10.1093/gerona/62.3.330

481 15. Shock NW. Normal human aging: The Baltimore longitudinal study of aging. Washington
482 D.C.: National Institute of Health; 1984.

Lindle RS, Metter EJ, Lynch NA, Fleg JL, Fozard JL, Tobin J, et al. Age and gender
comparisons of muscle strength in 654 women and men aged 20–93 yr. Journal of Applied
Physiology. 1997;83:1581-7. doi:10.1152/jappl.1997.83.5.1581

486 17. Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, et al. A short
487 physical performance battery assessing lower extremity function: association with self-reported
488 disability and prediction of mortality and nursing home admission. J Gerontol. 1994;49:M85-94.
489 doi:10.1093/geronj/49.2.m85

490 18. Zhou S, Zhang X-H, Zhang Y, Gong G, Yang X, Wan W-H. The Age-Adjusted Charlson
491 Comorbidity Index Predicts Prognosis in Elderly Cancer Patients. Cancer Management and Research.
492 2022;14:1683-91. doi:10.2147/CMAR.S361495

493 19. Gower BA, Nyman L. Associations among oral estrogen use, free testosterone concentration,
494 and lean body mass among postmenopausal women. J Clin Endocrinol Metab. 2000;85:4476-80.
495 doi:10.1210/jcem.85.12.7009

Bann D, Wu FC, Keevil B, Lashen H, Adams J, Hardy R, et al. Changes in testosterone
related to body composition in late midlife: Findings from the 1946 British birth cohort study. Obesity
(Silver Spring). 2015;23:1486-92. doi:10.1002/oby.21092

Sipilä S, Heikkinen E, Cheng S, Suominen H, Saari P, Kovanen V, et al. Endogenous
Hormones, Muscle Strength, and Risk of Fall-Related Fractures in Older Women. The Journals of
Gerontology: Series A. 2006;61:92-6. doi:10.1093/gerona/61.1.92

Rariy CM, Ratcliffe SJ, Weinstein R, Bhasin S, Blackman MR, Cauley JA, et al. Higher
serum free testosterone concentration in older women is associated with greater bone mineral density,
lean body mass, and total fat mass: the cardiovascular health study. J Clin Endocrinol Metab.
2011;96:989-96. doi:10.1210/jc.2010-0926

506 23. Hwang AC, Liu LK, Lee WJ, Chen LY, Lin MH, Peng LN, et al. Association of androgen with 507 skeletal muscle mass and muscle function among men and women aged 50 years and older in Taiwan: 508 results from the I-Lan longitudinal aging study. Rejuvenation Res. 2013:16:453-9. 509 doi:10.1089/rej.2013.1442

van Geel TA, Geusens PP, Winkens B, Sels JP, Dinant GJ. Measures of bioavailable serum
testosterone and estradiol and their relationships with muscle mass, muscle strength and bone mineral
density in postmenopausal women: a cross-sectional study. Eur J Endocrinol. 2009;160:681-7.
doi:10.1530/eje-08-0702

514 25. Kong SH, Kim JH, Lee JH, Hong AR, Shin CS, Cho NH. Dehydroepiandrosterone Sulfate
515 and Free Testosterone but not Estradiol are Related to Muscle Strength and Bone Microarchitecture in
516 Older Adults. Calcif Tissue Int. 2019;105:285-93. doi:10.1007/s00223-019-00566-5

517 26. Häkkinen K, Pakarinen A, Kallinen M. Neuromuscular adaptations and serum hormones in
518 women during short-term intensive strength training. Eur J Appl Physiol Occup Physiol. 1992;64:106519 11. doi:10.1007/bf00717946

520 27. Häkkinen K, Pakarinen A, Kraemer WJ, Häkkinen A, Valkeinen H, Alen M. Selective muscle
521 hypertrophy, changes in EMG and force, and serum hormones during strength training in older
522 women. J Appl Physiol (1985). 2001;91:569-80. doi:10.1152/jappl.2001.91.2.569

523 28. Yee ML, Hau R, Taylor A, Guerra M, Guerra P, Darzins P, et al. Sarcopenia in women with

524 hip fracture: A comparison of hormonal biomarkers and their relationship to skeletal muscle mass and

525 function. Osteoporos Sarcopenia. 2020;6:139-45. doi:10.1016/j.afos.2020.06.001

Pöllänen E, Sipilä S, Alen M, Ronkainen PH, Ankarberg-Lindgren C, Puolakka J, et al.
Differential influence of peripheral and systemic sex steroids on skeletal muscle quality in pre- and
postmenopausal women. Aging Cell. 2011;10:650-60. doi:10.1111/j.1474-9726.2011.00701.x

30. Bochud M, Ponte B, Pruijm M, Ackermann D, Guessous I, Ehret G, et al. Urinary Sex Steroid
and Glucocorticoid Hormones Are Associated With Muscle Mass and Strength in Healthy Adults. J
Clin Endocrinol Metab. 2019;104:2195-215. doi:10.1210/jc.2018-01942

532 31. Vaishya R, Misra A, Vaish A, Ursino N, D'Ambrosi R. Hand grip strength as a proposed new
533 vital sign of health: a narrative review of evidences. J Health Popul Nutr. 2024;43:7.
534 doi:10.1186/s41043-024-00500-y

S2. Carcaillon L, Blanco C, Alonso-Bouzón C, Alfaro-Acha A, Garcia-García FJ, RodriguezMañas L. Sex differences in the association between serum levels of testosterone and frailty in an
elderly population: the Toledo Study for Healthy Aging. PLoS One. 2012;7:e32401.
doi:10.1371/journal.pone.0032401

Huang G, Basaria S, Travison TG, Ho MH, Davda M, Mazer NA, et al. Testosterone doseresponse relationships in hysterectomized women with or without oophorectomy: effects on sexual
function, body composition, muscle performance and physical function in a randomized trial.
Menopause. 2014;21:612-23. doi:10.1097/gme.000000000000093

543 34. Cui J, Shen Y, Li R. Estrogen synthesis and signaling pathways during aging: from periphery
544 to brain. Trends Mol Med. 2013;19:197-209. doi:10.1016/j.molmed.2012.12.007

545 35. Vrtačnik P, Ostanek B, Mencej-Bedrač S, Marc J. The many faces of estrogen signaling.
546 Biochemia medica. 2014;24:329-42.

547 36. Colenso-Semple LM, D'Souza AC, Elliott-Sale KJ, Phillips SM. Current evidence shows no 548 influence of women's menstrual cycle phase on acute strength performance or adaptations to 549 resistance exercise training. Front Sports Living. 2023;5:1054542. Act 550 doi:10.3389/fspor.2023.1054542

551 37. Stricker R, Eberhart R, Chevailler M-C, Quinn F, Bischof P, Stricker R. Establishment of 552 detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and 553 progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT® analyzer. 554 Clinical chemistry and laboratory medicine CCLM / FESCC. 2006;44:883-7. : 555 doi:10.1515/CCLM.2006.160

556 38. Elliott-Sale KJ, Minahan CL, de Jonge X, Ackerman KE, Sipilä S, Constantini NW, et al.
557 Methodological Considerations for Studies in Sport and Exercise Science with Women as
558 Participants: A Working Guide for Standards of Practice for Research on Women. Sports Med.
559 2021;51:843-61. doi:10.1007/s40279-021-01435-8

Outcome variable		n	E2			FEI				ТТ		BioT			T/E Ratio		
			β	R^2	Р	β	R^2	Р									
Body composition	ALM (kg)	319	-0.02	0.32	0.72	0.07	0.33	0.13	-0.01	0.32	0.84	0.13	0.34	0.03	-0.06	0.33	0.18
	Relative appendicular lean mass (kg/kg total fat)	319	0.28	0.17	<0.01	0.20	0.14	0.02	0.11	0.12	0.06	-0.17	0.14	0.01	0.07	0.11	0.4
	Total body fat (%)	319	-0.30	0.15	<0.01	-0.21	0.11	<0.01	-0.14	0.10	<0.01	0.18	0.11	<0.01	-0.10	0.09	0.1
	Thigh muscle CSA (cm ²)	239	-0.08	0.41	0.15	0.01	0.41	0.89	-0.03	0.41	0.59	0.13	0.42	0.06	-0.08	0.41	0.0
	Thigh muscle (%)	239	0.19	0.23	<0.01	0.15	0.21	0.03	0.06	0.20	0.36	-0.10	0.20	0.12	0.01	0.20	0.8
	Muscle density (HU)	239	-0.02	0.26	0.67	-0.06	0.26	0.33	-0.02	0.26	0.81	-0.11	0.27	0.11	0.01	0.26	0.8
	Subcutaneous fat (cm ²)	239	-0.23	0.14	<0.01	-0.14	0.11	0.14	-0.05	0.09	0.38	0.19	0.12	0.01	-0.07	0.10	0.2
	Intramuscular fat (cm ²)	239	-0.07	0.05	0.33	0.02	0.04	0.80	0.00	0.04	0.96	0.28	0.11	<0.01	-0.11	0.05	0.0
Iuscle Function	Handgrip strength (kg)	319	0.02	0.42	0.80	0.04	0.43	0.41	0.02	0.42	0.69	0.05	0.43	0.30	-0.04	0.43	0.2
	Hamstring peak torque (Nm)																igi içi
	180d/s	319	-0.03	0.33	0.55	0.05	0.33	0.41	-0.02	0.33	0.63	0.03	0.33	0.58	-0.12	0.34	0.6
	30d/s	319	0.02	0.35	0.74	0.09	0.36	0.07	-0.02	0.35	0.64	0.03	0.35	0.55	-0.05	0.36	0.3
	Hamstring relative peak torque (Nm/kg LLM)																<u> </u>
	180d/s	319	-0.04	0.14	0.53	-0.02	0.14	0.73	-0.01	0.14	0.77	-0.03	0.14	0.50	-0.10	0.14	0.0
	30d/s	319	0.01	0.17	0.85	0.03	0.17	0.56	-0.02	0.17	0.65	-0.02	0.17	0.67	-0.03	0.17	0.
	Hamstring relative peak torque (Nm/cm ²)																c c
	180d/s	319	0.06	0.10	0.33	0.02	0.10	0.77	0.00	0.10	0.98	-0.11	0.11	0.09	-0.08	0.11	0.
	30d/s	319	0.06	0.10	0.28	0.05	0.10	0.48	0.02	0.10	0.73	-0.11	0.11	0.10	0.03	0.10	0.6
	Quadriceps peak torque (Nm)																
	180d/s	319	-0.06	0.45	0.25	-0.02	0.45	0.67	0.00	0.45	0.90	0.05	0.45	0.26	0.04	0.45	0.2
	30d/s	319	-0.03	-0.37	0.48	0.05	0.37	0.37	-0.02	0.37	0.69	0.05	0.37	0.35	0.03	0.37	0.4
	Quadriceps relative peak torque (Nm/kg LLM)																100
	180d/s	319	-0.07	0.32	0.22	-0.08	0.32	0.10	0.01	0.32	0.88	0.01	0.32	0.90	0.07	0.32	0.
	30d/s	319	-0.04	0.23	0.44	-0.02	0.22	0.78	-0.03	0.22	0.55	-0.01	0.22	0.86	0.07	0.23	0.1
	Quadriceps relative peak torque (Nm/cm ²)																
	180d/s	239	-0.02	0.25	0.76	-0.05	0.25	0.42	0.03	0.25	0.61	-0.08	0.25	0.30	0.04	0.25	0.5
	30d/s	239	-0.03	0.16	0.72	-0.01	0.16	0.89	0.03	0.16	0.54	-0.08	0.17	0.26	0.11	0.17	0.
Physical Function	400m walk time (s)	163	-0.01	0.29	0.94	0.08	0.30	0.63	0.02	0.30	0.66	0.11	0.31	0.04	0.06	0.30	0.0
	5 chair stand time (s)	203	0.30	0.08	0.11	0.19	0.08	0.32	-0.03	0.07	0.60	0.04	0.07	0.56	-0.06	0.07	0.

 $\frac{1}{265} = 0.03 = 0.03 = 0.03 = 0.03 = 0.01 = 0.03 = 0.07 = 0.00 = 0.00 = 0.$

Outcome variable			ΔΕ2			AFEI			ΔΤΤ			ΔΒίοΤ			Δ٦	io	
			β	R^2	Р	β	R^2	Р	β	R^2	Р	β	R^2	Р	β	\mathbf{R}^2	P
Body composition	Δ ALM (kg)	83	0.29	0.17	0.03	0.42	0.26	<0.01	-0.12	0.11	0.09	-0.14	0.11	0.28	-0.20	0.11	0.19
	Δ Relative appendicular lean mass (kg/kg total fat)	83	0.08	0.08	0.30	0.08	0.08	0.21	-0.25	0.15	<0.01	-0.25	0.13	<0.01	0.07	0.07	0.77
	Δ Total body fat (%)	83	-0.04	0.08	0.61	-0.06	0.08	0.41	0.10	0.09	0.11	0.16	0.10	0.07	-0.12	0.09	0.62
	Δ Thigh muscle CSA (cm ²)	61	0.06	0.13	0.65	0.04	0.12	0.72	0.13	0.15	0.10	0.13	0.14	0.15	0.03	0.12	0.88
	Δ Thigh muscle (%)	61	-0.10	0.06	0.27	-0.19	0.08	0.03	-0.03	0.05	0.58	-0.01	0.05	0.94	0.04	0.05	0.87 S
	Δ Muscle density (HU)	61	-0.03	0.06	0.79	-0.03	0.06	0.69	-0.04	0.06	0.42	0.02	0.06	0.83	0.10	0.06	0.59
	Δ Subcutaneous fat (cm ²)	61	0.17	0.14	0.12	0.28	0.17	0.01	0.08	0.12	0.08	0.05	0.12	0.73	-0.20	0.13	0.49
	Δ Intramuscular fat (cm ²)	60	0.19	0.10	0.20	0.28	0.17	0.03	-0.02	0.06	0.69	-0.02	0.06	0.83	-0.08	0.06	0.71
Muscle Function	Δ Handgrip strength (kg)	83	0.08	0.02	0.35	0.17	0.04	<0.01	0.02	0.01	0.83	0.04	0.01	0.70	-0.09	0.02	0.56
	Δ Hamstring peak torque (Nm)																ight
	180d/s	83	0.09	0.07	0.48	0.07	0.07	0.69	0.01	0.06	0.92	-0.04	0.07	0.77	-0.02	0.06	0.91 ត្ត
	30d/s	83	0.06	0.05	0.58	0.17	0.07	0.15	-0.06	0.05	0.32	-0.18	0.07	0.13	-0.16	0.06	0.45 e
	Δ Hamstring relative peak torque (Nm/kg LLM)																ed.
	180d/s	83	-0.02	0.12	0.91	-0.23	0.16	0.09	0.03	0.12	0.71	0.07	0.12	0.53	0.05	0.12	0.74 Z
	30d/s	83	0.05	0.03	0.66	-0.04	0.03	0.71	-0.01	0.02	0.93	-0.02	0.02	0.88	0.00	0.02	0.98 e
	Δ Hamstring relative peak torque (Nm/cm ²)																ë a
	180d/s		-0.04	0.11	0.75	-0.12	0.12	0.47	0.02	0.10	0.80	0.00	0.10	0.97	0.07	0.11	0.71
	30d/s		-0.02	0.05	0.83	0.01	0.05	0.90	-0.02	0.05	0.71	-0.12	0.06	0.22	-0.09	0.05	0.68
	Δ Quadriceps peak torque (Nm)	83															vith
	180d/s	83	-0.11	0.15	0.32	-0.31	0.22	<0.01	0.04	0.14	0.61	0.07	0.14	0.54	0.13	0.14	0.43 =
	30d/s		-0.07	0.04	0.60	-0.18	0.06	0.15	0.00	0.03	0.97	-0.01	0.03	0.96	0.09	0.04	0.63 e
	Δ Quadriceps relative peak torque (Nm/kg LLM)																niss
	180d/s	83	0.09	0.06	0.43	0.14	0.07	0.19	0.08	0.06	0.13	0.01	0.05	0.96	-0.08	0.05	0.75 9
	30d/s	83	0.02	0.07	0.84	0.16	0.10	0.22	-0.12	0.09	0.02	-0.27	0.12	0.04	-0.11	0.08	0.71
	Δ Quadriceps relative peak torque (Nm/cm ²)																Ś
	180d/s	83	-0.01	0.13	0.97	-0.17	0.16	0.28	0.04	0.14	0.49	0.07	0.14	0.54	-0.03	0.13	0.87
	30d/s	83	-0.03	0.05	0.78	-0.05	0.06	0.63	-0.06	0.06	0.32	-0.09	0.06	0.36	0.04	0.05	0.86
Physical Function	$\Delta 400$ m walk time (s)	50	-0.01	0.47	0.92	-0.07	0.48	0.36	0.14	0.50	0.08	0.23	0.51	0.03	0.10	0.48	0.43
	$\Delta 5$ chair stand time (s)	74	-0.02	0.06	0.81	0.00	0.06	0.95	-0.06	0.06	0.52	-0.05	0.06	0.75	-0.07	0.06	0.69

 Δ5 chair stand time (s)
 74
 -0.02
 0.06
 0.81
 0.00
 0.06
 0.95
 -0.06
 0.06
 0.75
 -0.07
 0.06
 0.69
 minder

 Multiple regression models were adjusted for age, ethnicity, height, ACCI, and total physical activity levels in the past two weeks. ALM: appendicular lean mass; BioT: bioavailable testosterone; CSA: cross-sectional area; E27 properties of total testosterone; T/E2: ratio of total testosterone to oestradiol.
 9.00 properties

 0
 0.05
 1.02
 0.06
 0.81
 0.00
 0.06
 0.95
 -0.05
 0.06
 0.75
 -0.07
 0.06
 0.69
 9.00

 Multiple regression models were adjusted for age, ethnicity, height, ACCI, and total physical activity levels in the past two weeks. ALM: appendicular lean mass; BioT: bioavailable testosterone; CSA: cross-sectional area; E27 properties

 0
 0.05
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02
 1.02